A 30-Minute Infusion of Isatuximab Is Safe, Feasible in Patients with Newly Diagnosed Multiple Myeloma

Source: Pharmacy Times articles

Isatuximab is a CD38-targeting monoclonal antibody that has demonstrated significant clinical success in improving minimal residual disease rates and progression-free survival.
Read More